The SALSA MLPA Probemix P087 BRCA1 Confirmation is an in vitro diagnostic (IVD)1
or a research use only (RUO) semi-quantitative assay2
for the detection of deletions or duplications in the human BRCA1
gene in genomic DNA isolated from human peripheral whole blood specimens. P087 BRCA1 Confirmation is intended to confirm a potential cause for and clinical diagnosis of hereditary breast and ovarian cancer (HBOC) syndrome, as initially determined using the SALSA MLPA Probemix P002 BRCA1. The P002 BRCA1 probemix should be used as a first tier probemix, as it provides a more extensive coverage of the BRCA1
Discordant results between the P087 BRCA1 Confirmation probemix and the P002 BRCA1 probemix should be investigated with a different technique.
Assay results are intended to be used in conjunction with other clinical and diagnostic findings, consistent with professional standards of practice, including clinical genetic evaluation, and counselling, as appropriate. The results of this test should be interpreted by a clinical molecular geneticist or equivalent.
This device is not intended to be used for standalone diagnostic purposes, pre-implantation or prenatal testing, population screening, or for the detection of, or screening for, acquired or somatic genetic aberrations, e.g from DNA extracted from formalin-fixed paraffin embedded (FFPE) or fresh tumour materials.
Please note that this probemix is for in vitro diagnostic use (IVD) in the countries specified at the end of the product description. In all other countries, the product is for research use only (RUO).
To be used in combination with a SALSA MLPA Reagent Kit and Coffalyser.Net analysis software.
Germline defects in the BRCA1
gene are the most frequent cause of a hereditary predisposition to breast cancer. Features characteristic of hereditary, versus sporadic, breast cancer are: younger age at diagnosis, frequent bilateral disease, and more frequent occurrence of disease among male relatives. Mutations in the BRCA1
genes account for about 20 to 25% of hereditary breast cancers and about 5 to 10% of all breast cancers. In addition, mutations in the BRCA1
genes account for around 15% of ovarian cancers overall.
More information is available at http://www.ncbi.nlm.nih.gov/books/NBK1247/
The great majority of germline defects in the BRCA1
gene are point mutations that can be detected by sequence analysis. Deletions and duplications of complete exons in the BRCA1
gene are the second most common cause of defects in the BRCA1
gene. These copy number changes are usually missed by amplicon-based sequencing analysis (Sanger sequencing or Next Generation Sequencing), but can be detected by the MLPA technique and hence MLPA complements sequence analysis of the BRCA1
gene. Large genomic rearrangements (LRGs) in BRCA1
may account for up to 25% of all disease-causing mutations, dependent on the population (Smith et al. 2011; Sluiter et al. 2011). For example in Italian hereditary breast and ovarian cancer (HBOC) families the prevalence is 23% (Montagna et al. 2003), in the Netherlands 27%-36% (Hogervorst et al. 2003; Petrij-Bosch et al. 1997), while in a Danish cohort of HBOC patients the prevalence was 3.8% (Thomassen et al. 2006).
The SALSA MLPA probemix P087-D1 BRCA1 Confirmation contains 40 MLPA probes with amplification products between 130 nt and 463 nucleotides (nt). This includes 28 probes for the BRCA1
At least one MLPA probe is present for each exon in the major BRCA1
transcript variant 1. Three probes are present for exon 11 and two probes for exon 1a and exon 13. To determine the extent of a deletion/duplication, one probe is present in the upstream region of BRCA1
(1.0 kb before exon 1a). In addition, 12 reference probes are included that detect autosomal chromosomal locations. Complete probe sequences and the identity of the genes detected by the reference probes are available online (www.mrcholland.com
This probemix contains nine quality control fragments generating amplification products between 64 and 105 nt: four DNA Quantity fragments (Q-fragments), two DNA Denaturation fragments (D-fragments), one Benchmark fragment, and one chromosome X and one chromosome Y-specific fragment (see table in the product description). More information on how to interpret observations on these control fragments can be found in the MLPA General Protocol and online at www.mrcholland.com
SALSA Artificial Duplication DNA SD024:
In case no positive DNA sample is available in your laboratory, an artificial duplication DNA sample for this probemix (catalogue number SD024) can be ordered from MRC Holland. This SD024 Artificial Duplication DNA will show a duplication of two or three probes when using the following probemixes: P002 and P087 BRCA1; P045, P090 and P077 BRCA2. The SD024 Artificial Duplication DNA is a mixture of human female genomic DNA and a titrated amount of plasmid containing selected probe target sequences. For further details, please consult the SD024 Artificial Duplication DNA product description, available online: www.mrcholland.com
. This product is for research use only (RUO).
Sample DNA developed for this product: